🧪 Evotec will provide long-term commercial supply of biosimilars to Sandoz from its biologics manufacturing facility in France.
🤝 The partnership aims to enhance access to biosimilars for patients and solidify Evotec’s strategy.
Introduction:
Just – Evotec Biologics has expanded its partnership with Sandoz to provide long-term commercial supply of biosimilars. Just – Evotec will receive payments for the early scientific validation of the agreement, with further funding tied to development milestones starting from 2025. The partnership aims to enhance access to biosimilars for millions of patients and ensure the long-term supply of Sandoz’s biosimilar portfolio.
- Just – Evotec Biologics has expanded its strategic partnership with Sandoz to provide long-term commercial supply of biosimilars.
- Just – Evotec will receive payments for the early scientific validation of the agreement, as well as funding tied to achieving development milestones from 2025.
- The partnership aims to enhance access to biosimilars for millions of patients and ensure the long-term supply of Sandoz’s biosimilar portfolio.
Conclusion:
This expanded partnership between Just – Evotec Biologics and Sandoz highlights the commitment to providing biosimilars and enhancing access for patients. The financial support provided by Sandoz will aid in the development of these biosimilars and ensure the long-term commercial supply. This partnership is a significant step forward in the advancement of biosimilar production and availability.
